Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Management of Complex Wounds Using a Constant Tension External Tissue Expander
NCT01171521
Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds
NCT01751282
Establishment of Cell Culture Systems From Discarded Operating Room Tissue
NCT01000077
Trial of Vacuum Assisted Closure® Therapy Versus Control Therapy in Angiogenesis
NCT00234559
Autologous Regenerative Technology (ART) For Wound Healing
NCT03368534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is reported to be physically and mentally able and willing to comply with the Protocol.
* Subject is between 18 - 75 years old.
Exclusion Criteria
* Reported presence of Acquired Immune Deficiency Syndrome.
* Reported presence of Hepatitis.
* Reported presence of cancer in the wound.
* Reported presence or suspected presence of infection (indicated by signs and symptoms of infection such as redness/swelling, or a positive culture, etc.)
* Presence of untreatable osteomyelitis.
* Presence of any other severe concurrent disease, which, in the judgment of the investigator, would make the subject inappropriate for entry into the study.
* Necrotic tissue with eschar present that cannot be debrided.
* Subject is unwilling or unable to comply with the protocol.
* Subject is a suspected or known intravenous drug user.
* Donation of tissue which, in the judgment of the investigator, may pose venous or arterial compromise.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
3M
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VACP2007-24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.